Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia
Closed
Phase 3
This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL).
Cancer Research UK supports this trial.
Recruitment start: 21 August 2014
Recruitment end: 19 January 2024
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Hillmen
Cancer Research UK
Abbvie
Janssen Pharmaceuticals
University of Leeds
This is Cancer Research UK trial number CRUK/12/037.
Last reviewed: 22 January 2024
CRUK internal database number: 10515
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
